<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228277</url>
  </required_header>
  <id_info>
    <org_study_id>KASTT005_BAL_Olita</org_study_id>
    <nct_id>NCT03228277</nct_id>
  </id_info>
  <brief_title>Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA</brief_title>
  <official_title>Phase II, Multicenter, Single-arm, Open-label Study to Evaluate the Efficacy of Olmutinib(Olita®) in Patients With NSCLC Who Harboring T790M Mutation Confirmed Using DNA Extracted From Extracellular Vesicles in Bronchoalveolar Lavage Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Konkuk University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Konkuk University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of Olmutinib(Olita®) in patients with&#xD;
      T790M-positive non-small cell lung cancer (NSCLC) confirmed using DNA extracted from&#xD;
      extracellular vesicles of bronchoalveolar lavage fluid.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, open-label, Phase 2 study to assess the anti-tumor efficacy of&#xD;
      Olmutinib(Olita®) administered to patients with T790M-positive NSCLC confirmed using DNA&#xD;
      extracted from extracellular vesicles in bronchoalveolar lavage fluid as measured by&#xD;
      objective response rate (ORR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 17, 2017</start_date>
  <completion_date type="Actual">July 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months</time_frame>
    <description>defined as the proportion of patients who achieved complete remission(CR) or partial remission(PR) based on RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months</time_frame>
    <description>defined as the proportion of patients with a documented CR, PR, and SD during the treatment cycles according to the RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Change from baseline at every 6 weeks until disease progression or withdrawal from study, assessed up to 12 months</time_frame>
    <description>defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Olmutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm of Olmutinib, staring dose of 800 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmutinib</intervention_name>
    <description>Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)</description>
    <arm_group_label>Olmutinib</arm_group_label>
    <other_name>Olita®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged at least 19 years&#xD;
&#xD;
          2. Obtained written informed consent&#xD;
&#xD;
          3. Histologically- or cytologically confirmed diagnosis of unresectable Stage IIIB or IV&#xD;
             non-small cell lung cancer.&#xD;
&#xD;
          4. Confirmation that the tumor harbours an EGFR mutation known to be associated with EGFR&#xD;
             TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q).&#xD;
&#xD;
          5. Eastern Cooperative Oncology Group performance status of 0 to 2&#xD;
&#xD;
          6. Prior treatment with at least one line of a single agent EGFR TKI (gefitinib,&#xD;
             erlotinib, afatinib) and confirmed progressive disease after treatment with EGFR TKI&#xD;
&#xD;
               -  Regardless of treatment sequence between previous chemotherapy and EGFR TKI&#xD;
&#xD;
               -  Regardless of whether they were administered conventional chemotherapy, if&#xD;
                  therapy were treated with at least one EGFR TKI&#xD;
&#xD;
          7. Subjects who will undergo bronchoscopy/ BAL procedures and sufficient amount of BAL&#xD;
             fluid is carefully collected for EGFR mutation analysis.&#xD;
&#xD;
          8. Confirmation that the extracellular vesicles (EV) extracted from bronchoalveolar&#xD;
             lavage fluid (BALF) harbour T790M mutation (It can be replaced previous the same&#xD;
             result throughout the follow up period before enrollment.)&#xD;
&#xD;
          9. At least one measurable disease (except brain) at baseline according to RECIST version&#xD;
             1.1&#xD;
&#xD;
         10. Female subjects must be postmenopausal (for at least one year), or, if sexually&#xD;
             active, be practicing an effective method of birth control (e.g., prescription oral&#xD;
             contraceptives, contraceptive injections, intrauterine device, double-barrier method,&#xD;
             contraceptive patch, male partner sterilization) before entry and throughout the&#xD;
             study; and, for those of childbearing potential, have a negative urinary β-hCG&#xD;
             pregnancy test at screening.&#xD;
&#xD;
         11. Male subjects should be willing to use barrier methods which are suitable for sexual&#xD;
             partner throughout the study.&#xD;
&#xD;
         12. Subjects must have signed an informed consent document indicating that they understand&#xD;
             the purpose of and procedures required for the study and are willing to participate in&#xD;
             the study. The subject also must sign and date the consent form before specific&#xD;
             procedures or sampling.&#xD;
&#xD;
         13. Adequate organ function as defined by liver, kidney, and hematologic laboratory&#xD;
             testing as below&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1500/mm3, Platelet ≥ 100,000 /mm3 Hemoglobin&#xD;
                  (Hb) ≥ 9.0g/dL&#xD;
&#xD;
               -  Serum creatinine ≤ upper limit of normal (ULN)&#xD;
&#xD;
               -  AST/ALT/ALP ≤ 3 times ULN, Total bilirubin ≤2.0 mg/dL AST/ALT/ALP ≤ 5 times ULN&#xD;
                  in patients with metastatic lesions to the liver ALP ≤ 5 times ULN in patients&#xD;
                  with metastatic lesions to the bone&#xD;
&#xD;
         14. Expected survival of at least 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with anticancer therapies, EGFR-TKI, olmutinib (HM61713), or other&#xD;
             drugs that target T790M-positive mutant EGFR with sparing of wild-type, Osimertinib&#xD;
             (AZD9291), Rociletinib (CO-1686), investigational agent(s) within 30 days prior to the&#xD;
             first administration of study drug, radiotherapy&#xD;
&#xD;
          2. Treatment with a potent cytochrome P450 (CYP) 3A4 inhibitors or inducers&#xD;
&#xD;
          3. History of any other malignancy EXCEPTIONS are:&#xD;
&#xD;
               -  adequately treated non-melanoma skin cancer, curatively treated in situ cancer of&#xD;
                  the cervix, ductal carcinoma in situ (DCIS) of the breast, thyroid cancer&#xD;
&#xD;
               -  other malignancies diagnosed prior to randomisation and treated with no evidence&#xD;
                  of disease recurrence more than 3 years&#xD;
&#xD;
          4. Any history or presence of clinically relevant cardiovascular abnormalities such as&#xD;
             uncontrolled hypertension, congestive heart failure NYHA classification of III or IV,&#xD;
             unstable angina or poorly controlled arrhythmia as determined by the investigator.&#xD;
             Myocardial infarction within 6 months prior to enrolment. Increased QTc interval &gt; 450&#xD;
             ms on screening ECG&#xD;
&#xD;
          5. Any history of presence of interstitial lung disease&#xD;
&#xD;
          6. Any history or presence of poorly controlled gastrointestinal disorders that could&#xD;
             affect the absorption of the trial drug (e.g. Crohn's disease, ulcerative colitis,&#xD;
             chronic diarrhea, malabsorption).&#xD;
&#xD;
          7. Ongoing active infection with, hepatitis B virus (infection defined as a positive&#xD;
             HbsAg and/ or HBV DNA), hepatitis C virus (infection defined as a positive HCV RNA),&#xD;
             or human immunodeficiency virus (HIV) Type 1/2 infection at the time of screening.&#xD;
&#xD;
          8. Known history of hypersensitivity to active or inactive excipients of study drug&#xD;
             (olmutinib) or drugs with a similar chemical structure of olmutinib&#xD;
&#xD;
          9. Subjects with galactose intolerance, Lapp lactase deficiency or glucose-galactose&#xD;
             malabsorption&#xD;
&#xD;
         10. Symptomatic or uncontrolled central nervous system (CNS) metastases (Patients are&#xD;
             eligible if they have completed their treatment and have recovered from the acute&#xD;
             effects of radiation therapy or surgery prior to the start of study medication, have&#xD;
             discontinued corticosteroid treatment for these metastases for at least 4 weeks and&#xD;
             are neurologically and radiologically stable)&#xD;
&#xD;
         11. Uncontrolled active infectious disease (with the exception of those that are&#xD;
             considered to be needed topical antibiotics, however subjects can be enrolled into the&#xD;
             study after they complete their treatment)&#xD;
&#xD;
         12. Unable to attend all the study visits or comply with study procedures&#xD;
&#xD;
         13. Patients who had received other investigational product within 30 days prior to the&#xD;
             first administration of study drug except for gefitinib, erlotinib, or afatinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kye Young Lee</last_name>
    <role>Principal Investigator</role>
    <affiliation>Konkuk University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Konkuk University Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05030</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 17, 2017</study_first_submitted>
  <study_first_submitted_qc>July 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2017</study_first_posted>
  <last_update_submitted>August 25, 2019</last_update_submitted>
  <last_update_submitted_qc>August 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Konkuk University Medical Center</investigator_affiliation>
    <investigator_full_name>Kye Young Lee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Extracellular vesicles</keyword>
  <keyword>Bronchoalveolar lavage fluid</keyword>
  <keyword>Liquid biopsy</keyword>
  <keyword>T790M</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Exosomes</keyword>
  <keyword>EGFR mutation testing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

